Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- ACC CardiaCast: Innovation in Action: Addressing Unmet Needs in Thrombotic ConditionsIn this episode, ACC Chief Innovation Officer Dr. Ami Bhatt is joined by ACC Vice President Dr. Roxana Mehran and Dr. Carolyn Lam to discuss thrombotic conditions and the importance of addressing gaps in treatment.
- Highlights From the Summer BOT RetreatEach year, the Board of Trustees (BOT) gathers for a three-day retreat to reflect on progress toward achieving the College's Mission and strategic goals. The retreat also provides dedicated time for longer-term planning and thoughtful discussion of opportunities, challenges and potential course corrections to ensure the College remains on track.
- New ACC/AHA Guideline Addresses Prevention, Detection, Evaluation and Management of High Blood PressureThe latest Clinical Practice Guideline from the ACC and the American Heart Association (AHA) and 11 other societies provides updated recommendations for clinicians on the prevention, detection, evaluation and management of high blood pressure in adults.
- AGENT IDE: Paclitaxel-Coated Balloon in Patients With Multilayer ISRTreating patients with multilayer in-stent restenosis (ISR) with a paclitaxel-coated balloon was associated with reduced risk of target lesion failure (TLF) at one year vs. an uncoated balloon, according to a subgroup analysis of the AGENT IDE trial published Aug. 11 in JACC.
- Does P2Y12 Inhibitor Monotherapy Reduce NACE, Bleeding in Patients With ACS After PCI?In patients with acute coronary syndrome (ACS) undergoing PCI, the benefits of shortening dual antiplatelet therapy (DAPT) vary based on monotherapy, with P2Y12 inhibitor monotherapy “significantly reducing†net adverse clinical events (NACE) and major bleeding, whereas aspirin monotherapy had “neutral results,â€...